Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 11Neoplasm Metastasis 7Neoplasms 5Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Neuroendocrine 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Renal Cell Cancer Metastatic 1Relapsed Pediatric Solid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Metatropic dwarfism 1Melanoma 1Lymphoma 1Liver Neoplasms 1Liver Failure 1Liver Diseases 1Liver Cirrhosis 1Leukemia, Myelomonocytic, Acute 1

Interventions

Thyroidectomy 1Pemetrexed 1Paclitaxel 1Lymph Node Excision 1Histocompatibility Testing 1Everolimus 1CCT239065 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Thyroid Carcinoma, Anaplastic × Everolimus × Clear all
NCT01118065 2013-08-12

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
42 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡